See our new HCP resources

Nurtec™ ODT (rimegepant) 75 mg Orally Disintegrating Tablets for Healthcare Professionals

Just one quick-dissolving dose can1:

Dissolve pain

Quick-dissolve tablet can start working in minutes to eliminate pain1-3

Dramatization of dissolving action.

Restore function

Proven to get many patients back to normal activities in as little as 1 hour1,2,4

Last up to 48 hours

Can keep patients functioning and free from migraine pain for up to 2 days—without rescue medication1,2,5

Half-life of 11 hours1

In a multi-center, double-blind, randomized, placebo-controlled study of 1351 patients (Nurtec ODT 75 mg, n=669; placebo, n=682), including patients with stable cardiovascular (CV) disease or CV risk factors1,2,4-6:

  • Co-primary endpoints at 2 h for Nurtec ODT vs placebo were pain freedom (21% vs 11%, P<.001) and freedom from most bothersome symptom (MBS; predefined as photophobia, phonophobia, or nausea; 35% vs 27%, P=.001).
  • Select secondary endpoints at 60 minutes for Nurtec ODT vs placebo were pain relief (37% vs 31%, P<.05) and return to normal function (22% vs 16%, P=.0025); from 2-48 h for Nurtec ODT vs placebo were pain freedom (14% vs 5%, P<.001), return to normal function (26% vs 15%, P<.0001), and pain relief (42% vs 25%, P<.0001).
See full study design

Formulary coverage for your patients

More than 220 million insured individuals
have access to Nurtec ODT

Nurtec ODT is the only preferred oral CGRP receptor antagonist on Anthem's national commercial formulary.

Nurtec ODT is the exclusive oral CGRP receptor antagonist on the BlueCross BlueShield Federal Employee Program commercial formulary.

Nurtec ODT is the only preferred CGRP receptor antagonist on TRICARE's formulary.

Find coverage in your area.


Error: Please provide a valid ZIP code.


Error: Please provide a valid NPI number.

Error: Please provide either a ZIP code or an NPI number.

Managed Markets Insights & Technology LLC as of 02/21

Real Patients,
Real Stories

Patients are challenging what life with migraine can look
like with Nurtec ODT, one dose and one story at a time.

See patient stories

Actual Nurtec ODT Patient

References: 1. Nurtec ODT. Package insert. Biohaven Pharmaceuticals Inc. 2. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. 3. Data on File. RIM108. Biohaven Pharmaceuticals, Inc. 4. Data on File. RIM107. Biohaven Pharmaceuticals Inc. 5. Data on File. RIM118. Biohaven Pharmaceuticals, Inc. 6. Data on File. RIM130. Biohaven Pharmaceuticals Inc.

Important Safety Information

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P‑gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: Pregnant/breast feeding: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. Hepatic impairment: Avoid use of Nurtec ODT in persons with severe hepatic impairment. Renal impairment: Avoid use in patients with end-stage renal disease.


Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.

Please click here for full Prescribing Information.